pERK Expression in Erlotinib-treated Patients with Advanced Pancreatic Cancer: a Translational Subgroup Analysis From the Randomized AIO-PK0104 Phase III Trial

被引：0
|
作者：
Boeck, S. [1 ,2 ]
Ormanns, S. [3 ]
Laubender, R. P. [4 ]
Jung, A. [3 ]
Siveke, J. T. [5 ]
Haas, M. [1 ,2 ]
Kirchner, T. [3 ]
Heinemann, V. [1 ,2 ]
机构：
[1] Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, D-8000 Munich, Germany
[2] Ctr Comprehens Canc, Munich, Germany
[3] Univ Munich, Dept Pathol, Munich, Germany
[4] Univ Munich, Inst Med Informat Biometry & Epidemiol, Munich, Germany
[5] Tech Univ Munich, Klinikum Rechts Isar, Dept Internal Med 2, D-8000 Munich, Germany
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)72275-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
477
引用
收藏
页码：148 / 148
页数：1
相关论文
共 50 条
  • [31] Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study
    Yamaue, Hiroki
    Tsunoda, Takuya
    Tani, Masaji
    Miyazawa, Motoki
    Yamao, Kenji
    Mizuno, Nobumasa
    Okusaka, Takuji
    Ueno, Hideki
    Boku, Narikazu
    Fukutomi, Akira
    Ishii, Hiroshi
    Ohkawa, Shinichi
    Furukawa, Masayuki
    Maguchi, Hiroyuki
    Ikeda, Masafumi
    Togashi, Yosuke
    Nishio, Kazuto
    Ohashi, Yasuo
    CANCER SCIENCE, 2015, 106 (07) : 883 - 890
  • [32] A phase III trial of virulizin plus gemcitabine vs. gemcitabine alone in advanced pancreatic cancer: Results of subgroup analysis.
    Wright, J. A.
    Osterlee, J.
    Fekete, S.
    Lee, Y.
    Young, A. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 206S - 206S
  • [33] Effect of weight loss in patients with metastatic colorectal cancer treated within the randomized phase III FIRE-3 trial (AIO KRK 0306)
    Liu, Lian
    Erickson, Nicole Tonya
    Holch, Julian W.
    Ricard, Ingrid
    Gesenhues, Alena Britta
    Theurich, Sebastian
    Stintzing, Sebastian
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [34] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
    Moore, Malcolm J.
    Goldstein, David
    Hamm, John
    Figer, Arie
    Hecht, Joel R.
    Gallinger, Steven
    Au, Heather J.
    Murawa, Pawel
    Walde, David
    Wolff, Robert A.
    Campos, Daniel
    Lim, Robert
    Ding, Keyue
    Clark, Gary
    Voskoglou-Nomikos, Theodora
    Ptasynski, Mieke
    Parulekar, Wendy
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) : 1960 - 1966
  • [35] A randomized phase II clinical trial of gemcitabine, oxaliplatin, erlotinib combination chemotherapy versus gemcitabine and erlotinib in previously untreated patients with locally advanced or metastatic pancreatic cancer.
    Lim, Sung Hee
    Yun, Jina
    Lee, Min-Young
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Namsu
    Lee, Kyu Taek
    Park, Sung Kyu
    Hong, Dae Sik
    Choi, Hyun Jong
    Moon, Jong Ho
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [36] Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
    Javier Cortés
    Hope S. Rugo
    Ahmad Awada
    Chris Twelves
    Edith A. Perez
    Seock–Ah Im
    Patricia Gómez-Pardo
    Lee S. Schwartzberg
    Veronique Diéras
    Denise A. Yardley
    David A. Potter
    Audrey Mailliez
    Alvaro Moreno-Aspitia
    Jin-Seok Ahn
    Carol Zhao
    Ute Hoch
    Mary Tagliaferri
    Alison L. Hannah
    Joyce O’Shaughnessy
    Breast Cancer Research and Treatment, 2017, 165 : 329 - 341
  • [37] Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
    Cortes, Javier
    Rugo, Hope S.
    Awada, Ahmad
    Twelves, Chris
    Perez, Edith A.
    Im, Seock-Ah
    Gomez-Pardo, Patricia
    Schwartzberg, Lee S.
    Dieras, Veronique
    Yardley, Denise A.
    Potter, David A.
    Mailliez, Audrey
    Moreno-Aspitia, Alvaro
    Ahn, Jin-Seok
    Zhao, Carol
    Hoch, Ute
    Tagliaferri, Mary
    Hannah, Alison L.
    O'Shaughnessy, Joyce
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 165 (02) : 329 - 341
  • [38] Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'
    Boeck, Stefan
    Vehling-Kaiser, Ursula
    Waldschmidt, Dirk
    Kettner, Erika
    Maerten, Angela
    Winkelmann, Cornelia
    Klein, Stefan
    Kojouharoff, Georgi
    Gauler, Thomas
    von Weikersthal, Ludwig Fischer
    Clemens, Michael R.
    Geissler, Michael
    Greten, Tim F.
    Hegewisch-Becker, Susanna
    Neugebauer, Sascha
    Heinemann, Volker
    ANTI-CANCER DRUGS, 2010, 21 (01) : 94 - 100
  • [39] Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer
    Chung, Hyun Cheol
    Kok, Victor C.
    Cheng, Rebecca
    Hsu, Yanzhi
    Orlando, Mauro
    Fuchs, Charles
    Cho, Jae Yong
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (03) : 204 - 209
  • [40] IPILIMUMAB IMPROVES SURVIVAL IN PREVIOUSLY TREATED, ADVANCED MELANOMA PATIENTS WITH POOR PROGNOSTIC FACTORS: SUBGROUP ANALYSES FROM A PHASE III TRIAL
    Lebbe, C.
    McDermott, D. F.
    Robert, C.
    Lorigan, P.
    Ottensmeier, C. H.
    Wolchok, J.
    Garbe, C.
    Messina, M.
    Hoos, A.
    Weber, J. S.
    ANNALS OF ONCOLOGY, 2010, 21 : 401 - 401
12345